| Basics |
ABBVIE INC.
AbbVie Inc is a biopharmaceutical company that discovers, develops, manufactures and sells a range of pharmaceutical products for treating chronic autoimmune diseases, virology and neurological disorders.
|
| IPO Date: |
December 14, 2012 |
| Sector: |
Healthcare |
| Industry: |
Drug Manufacturers |
| Market Cap: |
$337.14B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.98 | 1.02%
|
| Avg Daily Range (30 D): |
$1.80 | 0.98%
|
| Avg Daily Range (90 D): |
$2.63 | 1.37%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
6.32M |
| Avg Daily Volume (30 D): |
4.68M |
| Avg Daily Volume (90 D): |
5.4M |
| Trade Size |
| Avg Trade Size (Sh.): |
108 |
| Avg Trade Size (Sh.) (30 D): |
55 |
| Avg Trade Size (Sh.) (90 D): |
57 |
| Institutional Trades |
| Total Inst.Trades: |
60,689 |
| Avg Inst. Trade: |
$9.52M |
| Avg Inst. Trade (30 D): |
$23.47M |
| Avg Inst. Trade (90 D): |
$24.23M |
| Avg Inst. Trade Volume: |
.09M |
| Avg Inst. Trades (Per Day): |
19 |
| Market Closing Trades |
| Avg Closing Trade: |
$88.06M |
| Avg Closing Trade (30 D): |
$213.08M |
| Avg Closing Trade (90 D): |
$245.91M |
| Avg Closing Volume: |
797.83K |
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q3 2024 |
|
Basic EPS
|
|
$.72
|
$.88
|
|
Diluted EPS
|
|
$.72
|
$.88
|
|
Revenue
|
$
|
$ 13.34B
|
$ 14.46B
|
|
Gross Profit
|
$
|
$ 9.34B
|
$ 10.25B
|
|
Net Income / Loss
|
$
|
$ 1.29B
|
$ 1.56B
|
|
Operating Income / Loss
|
$
|
$ 3.73B
|
$ 3.83B
|
|
Cost of Revenue
|
$
|
$ 4B
|
$ 4.21B
|
|
Net Cash Flow
|
$
|
$ -349M
|
$ -5873M
|
|
PE Ratio
|
|
|
|
|
|
|
